InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receive First Payment on ‘Milestone’ Purchase of Cancer Detection Equipment
March 7, 2023
AnPac Bio-Medical Science (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection, received the first payment in late February 2023 from a Malaysian customer that had purchased AnPac Bio’s Model AP9080 cancer detection devices. The contract for these devices totaled $1.5 million. According to the announcement, the proprietary Model AP9080 features […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces US$5M Private Placement
March 6, 2023
AnPac Bio (NASDAQ: ANPC) is a company with operations in the United States and China focused on early cancer screening and detection with plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian-sourced food products. The company today announced its entry into definitive investment agreements with certain […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Reports Positive Results from Multiyear, Multicancer Follow-Up Study
February 22, 2023
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and with plans to enter into the operation of a business-to-business (“B2B”) e-commerce food platform focused on the sale of Asian-sourced food products, is releasing information on the results of a major follow-up […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Acquires GISN to Enhance Efficiency of e-Commerce Operations
February 15, 2023
AnPac Bio (NASDAQ: ANPC), a company with operations in the United States and China, is engaged in early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian-sourced food products. The company today announced the closing of the acquisition of GISN (HK) […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Inks Acquisition Deal to Expand in the US
February 13, 2023
AnPac Bio-Medical Science (NASDAQ: ANPC), a company with operations in the United States and China, and its subsidiary Foodbase Group Inc, have signed a definitive equity purchase agreement; the agreement outlines the acquisition of a group of affiliated companies: SLV Windfall Group LLC, Windfall SLV Development LLC and SLV Windfall Management LLC. These companies are engaged in developing, […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Signs Agreement to Acquire a B2B Asian Food E-Commerce Platform
February 9, 2023
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and with plans to enter into the operation of a business-to-business (“B2B”) e-commerce food platform focused on the sale of Asian-sourced food products, has signed a definitive agreement to acquire Fresh2 Ecommerce Inc. […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Signs $5.2M of Definitive Investment Agreements
January 25, 2023
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and a business-to-business (“B2B”) food e-commerce company, announced that in December 2022 and January 2023, the company signed definitive agreements with several third party investors. According to the update, the investors agreed to […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Report Noting 48.8% Decrease in 2022 Net Loss
December 20, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, is reporting its unaudited financial results for the six months ended June 30, 2022. Highlights of the report for the first half of 2022 include total revenue of an estimated $778,000, a decrease of 43.7% compared to the same period […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces $5M Private Placement, Formation of Fresh2 Technology Inc.
December 5, 2022
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced that it has reached a mutual understanding with nine investors. Through a private placement, the investors will subscribe for and purchase from the company a total of 28,571,428 newly issued Class […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Regains Compliance with Nasdaq Listing Requirement
November 30, 2022
AnPac Bio (NASDAQ: ANPC) is a biotechnology company with operations in the United States and China focused on early cancer screening and detection. The company today announced that it has been notified by the Office of the General Counsel of The Nasdaq Stock Market LLC that it has regained compliance with the minimum $1 per […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Board of Directors Sees Changes
November 10, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, is announcing changes to its board of directors and management team. According to the announcement, both Yuyang Cui and Jiawen Kang have resigned. Cui was serving as cochair of the board and […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Continued Listing Status Granted by NASDAQ Hearing Panel
November 4, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, is able to continue to list its shares on the NASDAQ Capital Market. The company received the notification from Nasdaq Hearings Panel of the Listing Qualifications Department of the Nasdaq Stock Market […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Plans to Implement ADS Ratio Change
October 18, 2022
AnPac Bio (NASDAQ: ANPC) is a biotechnology company with operations in the United States and China focused on early cancer screening and detection. The company today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its Class A ordinary shares from one (1) ADS representing one (1) Class A […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names New Board Members, Management Changes
October 4, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has made changes in its board membership and on its management team. The company announced that Haohan Xu has been appointed as a director of the board of directors (the “Board”); he […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements
September 27, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has entered into legally binding investment agreements with nine institutional and individual investors; the agreements outline an investment in the company of approximately $3.67 million. According to the announcement, the various shares purchase […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces NASDAQ Delisting Appeal, Hearing
September 19, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has filed a request with the NASDAQ Hearings Panel to appeal its delisting. The appeal, which was filed on Sept. 16, 2022, requests a hearing so that the company can present its […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names New Board Members, Co-CEO
August 8, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has appointed a new board member as well as a new board chair and co-CEO. ANPC board of directors announced that Jiawen Kang will be serving as a member of the board […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Announcement Regarding Changes in Directors, Officers and Committees
July 19, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has announced changes in the company’s directors and officers. The announcement stated that, on July 14, 2022, the company’s member approved written resolutions of a majority of the members. The resolutions addressed […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Regains Compliance to Remain Listed on Nasdaq Capital Market
June 10, 2022
AnPac Bio (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection, today announced that The Nasdaq Stock Market LLC has determined that it has regained compliance with the requirements to remain listed on The Nasdaq Capital Market, as required by a hearing panel’s decision dated May 4, 2022, subject to a one-year […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial Report for FY 2021
June 1, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, is reporting its financial results for the first quarter of fiscal year 2022, or the period ended March 31, 2022. The numbers are unaudited and have not yet been reviewed by the […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial Report for FY 2021
May 17, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, is reporting its annual financial results for the year ended December 31, 2021. Highlights of the report include total revenues of $2.8 million, down 12.3% from $3.1 million in fiscal year 2020, along with […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Regains Compliance with MVPHS Requirement
May 11, 2022
AnPac Bio (NASDAQ: ANPC) is a biotechnology company with operations in the United States and China focused on early cancer screening and detection. The company today announced its receipt of notification from the Nasdaq Stock Market LLC that ANPC’s American Depositary Shares are now in compliance with the maintenance of the minimum market value of […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives Nasdaq Approval to Transfer Markets
May 6, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, announced that its request to transfer its American Depositary Shares from the Nasdaq Global Market to the Nasdaq Capital Market has been approved. The company anticipates continuing to list on the Nasdaq […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces New Appointments, Enters New Investment Agreement
April 11, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has named a new CEO. Dr. Ai-dong Chen will be taking over the helm, replacing Dr. Chris Yu, AnPac founder, who resigned as board director, CEO and board chair. Chen was also […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Subsidiary Appraised, Approved to Explore Strategic Alternatives
March 3, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary Changwei System Technology (Shanghai) Co. Ltd. has been evaluated and appraised by China Alliance Appraisal (Shanghai) Co. Ltd. One of the top 10 appraisers in China by revenue, China Alliance is certified and licensed by the China Appraisal Society under the Ministry of Finance. Fully owned by AnPac Bio, […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Breakthrough Medical Device Designation with FDA
February 3, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has filed for a breakthrough device designation request for its cancer differentiation analysis (“CDA”) technology-based medical device; the company filed the request with the Food and Drug Administration (“FDA”) earlier this week. […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Ranked No. 1 Globally in Multi-Cancer Screening and Detection Test Volume
January 25, 2022
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that Frost & Sullivan Company, a leading and well-known U.S. market analysis and research firm, has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research report. Based on […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Proprietary Medical Device Passes Registration Tests, Slated to Start Clinical Trial
January 4, 2022
AnPac Bio-Medical Science (NASDAQ: ANPC), a U.S.- and China-based biotechnology company focused on early cancer screening and detection, announced that its Class III medical device for lung cancer auxiliary diagnosis has passed stringent and rigorous registration tests; the tests were conducted at a testing laboratory selected by China’s regulatory agent for medical products, the National […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Publication of Technical Paper on Biophysics-Based CDA Cancer Detection Technology
December 10, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its joint technical paper on novel Cancer Differentiation Analysis (“CDA”) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online. The piece was published on Nov. 30 by the Expert Review of Molecular […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial, Operations Report for Latest Period
November 29, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reported its unaudited financial results and business highlights for the nine months ended Sept. 30, 2021. Financial highlights include total revenue reaching an estimated $2.1 million, which is a 55.3% over […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Uniquely Positioned in Cancer Screening, Detection Market
November 15, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is the company behind a proprietary novel technology for early cancer screening and detection — the Cancer Differentiation Analysis (“CDA”). Powered by a database containing over 200,000 samples and cases, AnPac Bio’s CDA technology can detect and carry multifaceted information, […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Issues Update on Underwritten Public Offering of American Depositary Shares
November 11, 2021
AnPac Bio (NASDAQ: ANPC) today issued a correction to its press release dated Nov. 9, 2021, regarding the pricing of its underwritten public offering of American Depositary Shares (“ADSs”). According to the update, the original release referenced the dollar size of the offering and the number of ADSs being sold to include the exercise of […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Begin Proposed Public Offering
November 10, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced that it is starting an underwritten public offering; the offering is comprised of ANPC’s American Depositary Shares and is subject to market and other conditions. The announcement noted that there is […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Participate in Q4 Virtual Investor Summit
November 8, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov. 16–17, 2021. According to the announcement, AnPac head of investor relations, Phil Case, will present at the two-day event; AnPac’s […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging CDA Technology for Critical Early Cancer Detection
October 29, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, since 2015 has commercially proven out its concepts through the development and sale of its cancer detection technology, Cancer Differentiation Analysis (“CDA”) for early detection of pre-cancerous disease and cancer. “The company has published numerous reports of clinical study results […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening
October 22, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is […]
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection
October 12, 2021
Blood and genomic testing are becoming preferable means of early cancer screening and detectionLeaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and GuardantAnPac Bio-Medical’s testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test data base) that detect up to 26 […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment
October 11, 2021
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer
October 4, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reached a significant milestone and positive result in its general-population, cancer-risk assessment tests and subsequent follow-up study. At the end of September 2021, healthcare providers confirmed more than 2,000 cancer, precancer […]
InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%
October 1, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released it unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total revenues reaching an estimated $1.4 million, an increase of 128.5% compared to the same period in 2020; gross profit margin […]